Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Rapid Micro Biosystems's Revenue for the
three
months ended in Mar. 2026 was $8.00 Mil. Rapid Micro Biosystems's average Accounts Receivable for the
three
months ended in Mar. 2026 was $4.75 Mil.
Hence, Rapid Micro Biosystems's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.68.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Rapid Micro Biosystems Receivables Turnover Related Terms
Rapid Micro Biosystems Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Rapid Micro Biosystems's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RPID vs OM, NNOX, STIM: Receivables Turnover Comparison
For the Medical Devices subindustry, Rapid Micro Biosystems's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapid Micro Biosystems Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Rapid Micro Biosystems's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Rapid Micro Biosystems's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapid Micro Biosystems (RPID) has a Receivables Turnover of 1.68 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Rapid Micro Biosystems and its competitors. According to the industry distribution chart, Rapid Micro Biosystems ranks #278 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 34.2%.
Is Rapid Micro Biosystems' Receivables Turnover too high?
Rapid Micro Biosystems' current Receivables Turnover is 1.68. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Rapid Micro Biosystems' value of 1.68 is 69.5% below this industry median. Based on the distribution chart, Rapid Micro Biosystems ranks #278 out of 812 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Rapid Micro Biosystems has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Rapid Micro Biosystems' Receivables Turnover compare to OM and NNOX?
According to the Medical Devices & Instruments industry distribution chart, Rapid Micro Biosystems ranks #278 out of 812 companies for Receivables Turnover. This puts Rapid Micro Biosystems in the upper half of its industry. The industry median Receivables Turnover is 5.51. Rapid Micro Biosystems' value of 1.68 is 69.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rapid Micro Biosystems's current Receivables Turnover of 1.68 is 69.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Rapid Micro Biosystems and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rapid Micro Biosystems's current Receivables Turnover is 1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Micro Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Rapid Micro Biosystems (RPID) is currently considered Fairly Valued. The stock's GF Value™ is $1.90, compared to a current price of $2.06 — trading 8.2% above its estimated fair value. The current Receivables Turnover is 1.68 and 69.5% below the Medical Devices & Instruments industry median of 5.51. Rapid Micro Biosystems' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Rapid Micro Biosystems (RPID), the current Receivables Turnover is 1.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rapid Micro Biosystems (RPID) Overvalued in 2026?
Based on GuruFocus' analysis, Rapid Micro Biosystems stock appears to be overvalued.
The current stock price of $2.06 is trading 8.2% above its estimated GF Value™ of $1.90.
GuruFocus considers Rapid Micro Biosystems to be Fairly Valued.
Key valuation signals for RPID:
Receivables Turnover: 1.68
GF Value™: $1.90 vs. price of $2.06 (8.2% above fair value)
Industry Position: 69.5% below the Medical Devices & Instruments median (#278 of 812)
No single metric tells the full story. See the RPID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.
59GF Score
Get the complete analysis for RPID
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPID has been successfully added to your 
